These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


63 related items for PubMed ID: 2498186

  • 1. Results of two different conditioning regimens followed by ABMT in refractory acute lymphoblastic leukemia.
    Meloni G, De Fabritiis P, Pulsoni A, Sandrelli A, Giona F, Simone F, Mandelli F.
    Haematologica; 1989; 74(1):67-70. PubMed ID: 2498186
    [Abstract] [Full Text] [Related]

  • 2. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S.
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
    Snyder MJ, Johnson DB, Daly MB, Giguere JK, Harman GH, Harden EA, Johnson RA, Leff RS, Mercier RJ, Messerschmidt GL.
    Bone Marrow Transplant; 1994 Oct; 14(4):595-600. PubMed ID: 7858534
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update.
    Linker CA, Damon LE, Ries CA, Rugo HS, Wolf JL.
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):40-8; quiz 49. PubMed ID: 8342075
    [Abstract] [Full Text] [Related]

  • 11. Autologous bone marrow transplantation in patients with AML in first complete remission. Results of two different conditioning regimens after the same induction and consolidation therapy.
    Meloni G, De Fabritiis P, Carella AM, Mangoni L, Porcellini A, Marmont A, Mandelli F.
    Bone Marrow Transplant; 1990 Jan; 5(1):29-32. PubMed ID: 2404528
    [Abstract] [Full Text] [Related]

  • 12. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Acute lymphoblastic leukemia in young adults: two chemotherapeutic protocols for the treatment of 46 patients.
    Ho CL, Chen YC, Kao WY, Chao TY.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan; 63(1):45-52. PubMed ID: 10645050
    [Abstract] [Full Text] [Related]

  • 15. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [Abstract] [Full Text] [Related]

  • 16. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
    Weaver CH, Schwartzberg L, Rhinehart S, West J, Zhen B, West WH, Buckner CD.
    Bone Marrow Transplant; 1998 Feb; 21(4):383-9. PubMed ID: 9509973
    [Abstract] [Full Text] [Related]

  • 17. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy.
    Kröger N, Hoffknecht M, Hänel M, Krüger W, Zeller W, Stockschläder M, de Wit M, Weh HJ, Kabisch H, Erttmann R, Zander AR.
    Bone Marrow Transplant; 1998 Jun; 21(12):1171-5. PubMed ID: 9674847
    [Abstract] [Full Text] [Related]

  • 18. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [Abstract] [Full Text] [Related]

  • 19. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma.
    Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ, Shin HJ, Jung JS, Kim WS, Kim DH, Suh C, Kim SJ, Eom HS, Bae SH.
    Bone Marrow Transplant; 2007 Nov; 40(10):919-24. PubMed ID: 17846602
    [Abstract] [Full Text] [Related]

  • 20. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
    Matsuyama T, Kojima S, Kato K.
    Bone Marrow Transplant; 1998 Jul; 22(1):21-6. PubMed ID: 9678791
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 4.